Please login to the form below

Aimmune

This page shows the latest Aimmune news and features for those working in and with pharma, biotech and healthcare.

DBV refiles peanut allergy immunotherapy in the US

four to 11 years, as it tries to catch up with a rival programme from US company Aimmune Therapeutics that is already under FDA review. ... Aimmune is expecting an approval decision on AR101 by January 2020, and the FDA has planned an advisory committee

Latest news

Aimmune wins over ICER for peanut allergy product

Analysts predict blockbuster status for first-in-class. Aimmune is still a few months away from a potential US approval of its peanut allergy drug AR-101, but already has a ... derailed. Meanwhile, Aimmune also seems to be in the lead in Europe, with a
Aimmune preps EU filing for peanut allergy immunotherapy

Company set to be first to market. US biotech Aimmune has a positive European phase 3 study for its peanut allergy therapy AR101 to match its US trial, setting up an ... Subjects in the study were given escalating doses of AR101 over six months to induce
FDA moves into crisis mode as shutdown drags on

One company – Aimmune Therapeutics – has already said it has been notified that as a direct result of the shutdown, the FDA will not commence review of its marketing application for peanut
VCCP Health lands record haul at the PM Society Awards

Craft Award for Disease Awareness (HCPs) - Solaris Health &Watchable for Aimmune.
Nestlé Health Science invests $145m in food allergy biotech

The deal will also see Nestlé Health Science's CEO Greg Behar take a seat on the Aimmune Board. ... Aimmune's lead candidate is AR101 for peanut allergy, which is among the top eight food allergies and estimated to impact 6 million people in the US and

More from news
Approximately 4 fully matching, plus 2 partially matching documents found.

Latest Intelligence

Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

Forecast sales for Skyrizi in 2023 are $1.74bn. AR-101 from Aimmune Therapeutics addresses peanut allergy. ... However, Aimmune reported in February 2019 that the FDA had initially determined that the drug, as an allergenic extract, was exempt from the
Drug launches to watch in 2019

Now a US biotech company, Aimmune, looks set to bring the first treatment to market by the end of this year. ... Aimmune Therapeutics submitted the drug to the FDA on 21 December.
Deal Watch November 2016

licence, collaboration. 167. Aimmune Therapeutics/ Nestlé Health Science. CODIT (Characterised Oral Desensitisation ImmunoTherapy), for treating life-threatening food.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Account Director – UK Office: Excellent salary and benefits

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

FREELANCE Account Director – Healthcare Advertising – London – 3...: Competitive Daily Rates

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Account Director, Healthcare Communications: Salary TBC

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Account Director - Healthcare Advertising - London - 2 DAYS HOME...: £50000 - £70000

Senior Account Executive – Account Manager – Healthcare Advertis...: £32000 - £43000 Bonus Benfits

Subscribe to our email news alerts

PMHub

Add my company

Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Empowered patients: shaking the foundations of healthcare: Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service: The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence: Data is the most valued commodity of the modern world. For P&P it's all about the application....